Related Experiment Videos
Methyl-methacrylate bone cement surface does not promote platelet aggregation or plasma coagulation in vitro
Ales Blinc1, Mojca Bozic, Rok Vengust
1Department of Vascular Diseases, University of Ljubljana Medical Centre, Zaloska 7, 1525, Slovenia. ales.blinc@trnovo.kclj.si
Thrombosis Research
|September 3, 2004
Summary
Bone cement surfaces do not cause blood clotting during vertebroplasty. However, bone cement liquid inhibits platelet aggregation and plasma clotting in vitro at high concentrations.
Area of Science:
- Biomaterials Science
- Hematology
- Orthopedic Surgery
Background:
- Percutaneous vertebroplasty (PVP) involves injecting bone cement, with potential leakage into venous circulation.
- This leakage can lead to serious complications like pulmonary embolism.
- The thrombogenic potential of bone cement components needs investigation.
Purpose of the Study:
- To evaluate the in vitro thrombogenicity of bone cement surfaces and liquid components.
- To determine if bone cement induces platelet aggregation or plasma coagulation.
Main Methods:
- Two methyl-methacrylate bone cements (Palacos, Vertebroplastic) were tested.
- Bone cement surfaces on glass slides were assessed for platelet aggregation.
- Bone cement liquid components were tested for effects on platelet aggregation and partial thromboplastin time (PTT).
Main Results:
- Bone cement surfaces, fresh or aged, did not induce significant platelet aggregation.
- Bone cement liquids inhibited collagen-induced platelet aggregation (<15%).
- Bone cement liquids significantly prolonged PTT, indicating plasma anticoagulation effects.
Conclusions:
- The surface of bone cement is not thrombogenic in vitro.
- Bone cement liquid components exhibit anticoagulant properties in vitro at high concentrations.
- These findings suggest a low risk of thrombotic complications directly from bone cement itself during PVP.